A Phase 3 interventional study of Obinutuzumab and Bendamustine in Non-Hodgkin's Lymphoma, sponsored by Genentech, Inc.. Completed at 121 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. obinutuzumab · Lymphoma, Non-Hodgkin.
Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, this one is the 3rd largest by enrollment, is the only one that started in 2010, is one of 2 in phase 3, and was the 2nd registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
New York Medical College · Sites in United States
Ages 3–31
Henan Cancer Hospital
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 41 across the 15 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 10th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2010, is one of 11 in phase 3, and was the 15th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
3 of the studies testing obinutuzumab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT04077723Hoffmann-La RocheA Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | 2026-12-28 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This open-label, multicenter, randomized Phase III study will investigate the efficacy, safety, pharmacokinetics and pharmacoeconomics of obinutuzumab (RO5072759, GA101) combined with bendamustine followed by continued obinutuzumab treatment (maintenance monotherapy) compared with bendamustine alone treatment in participants with rituximab-refractory indolent Non-Hodgkin's lymphoma (iNHL). The end of study was defined to when safety follow-up for all patients had been completed (2 years' safety follow-up from last dose).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive bendamustine 120 milligrams per meter square (mg/m\^2) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.
Drug: Bendamustine
Induction phase: Participants will receive bendamustine 90 mg/m\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants will also receive obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with complete response (CR), partial response (PR) or stable response (SD) then will receive obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurs first).
Drug: Obinutuzumab · Drug: Bendamustine
IV infusion.
Also known as: RO5072759; GA101
IV infusion.
Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death
PD was assessed by an IRC according to the modified response criteria for indolent Non-Hodgkin's Lymphoma (iNHL) (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50 percent (%) increase from nadir in the sum of product diameter (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (example: splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of less than (\<) 1.0 cm must increase by greater than or equal to (≥) 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node greater than (\>) 1 cm in its short axis.
Time frame: Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cycle [Cy] 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])
Progression-Free Survival (PFS) as Assessed by IRC
PFS was defined as the time from randomization to the first occurrence of PD or death as assessed by an IRC according to the modified response criteria for iNHL (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])
Number of Participants With PD or Death as Assessed by Investigator
PD was assessed by an investigator according to the modified response criteria for iNHL (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis.
Time frame: Baseline until PD or death, whichever occurred first (up to 8.5 years overall))
PFS as Assessed by Investigator
PFS was defined as the time from randomization to the first occurrence of PD as assessed by an investigator according to the modified response criteria for iNHL (Modified Cheson et al, 2007), or death from any cause on study. PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline until PD or death, whichever occurred first (up to 8.5 years overall)
Percentage of Participants With Objective Response as Assessed by IRC
Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. IRC review was performed up clinical cutoff date of to 1 May 2015.
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Percentage of Participants With Objective Response as Assessed by Investigator
Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)
Percentage of Participants With Best Overall Response (BOR) as Assessed by IRC
BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan \& no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic \& hepatic nodules, involvement of other organs is usually assessable \& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions (e.g., splenic or hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator
BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain the criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)
Percentage of Participants With BOR at the End of Induction Treatment as Assessed by IRC
BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan \& no new sites; no increase in size of other nodes, liver or spleen; with exception of splenic \& hepatic nodules, involvement of other organs is usually assessable \& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or size of other lesions (e.g., splenic/hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.
Time frame: Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)
Percentage of Participants With BOR at the End of Induction Treatment as Assessed by Investigator
BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).
Time frame: Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)
Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC
Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. IRC review was performed up clinical cutoff date of to 1 May 2015.
Time frame: Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)
Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by Investigator
Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
Time frame: Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)
Duration of Response (DoR) as Assessed by IRC
DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable evidence of disease \& disease-related symptoms if present before therapy; liver, spleen returned to normal size; if bone marrow involved by lymphoma before treatment, infiltrate must be cleared on repeat bone marrow biopsy. PR: at least 50% measurable disease regressed vs. to baseline scan and no new sites; no increase in size of other nodes/liver/spleen, exception: splenic, hepatic nodules; other organs involved is usually assessable; no measurable disease present. PD: any new lesion \>1.5 cm in any axis appear during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR estimated using Kaplan-Meier method. IRC review performed up to clinical cutoff date 1 May 2015.
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Duration of Response (DoR) as Assessed by Investigator
DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy; liver, spleen returned to normal size (if enlarged at baseline); if bone marrow was involved by lymphoma prior to treatment, infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic, hepatic nodules; involvement of other organs is usually assessable; no presence of measurable disease. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR was estimated using Kaplan-Meier method.
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)
Disease-Free Survival (DFS) in Participants With CR as Assessed by IRC
DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method. IRC review was performed up clinical cutoff date of to 1 May 2015.
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Disease-Free Survival (DFS) in Participants With CR as Assessed by Investigator
DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method.
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)
Event-free Survival (EFS) as Assessed by IRC
EFS was defined as the time between the date of randomization and the date of PD/relapse based on IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]), death from any cause on study, or start of a new anti-lymphoma therapy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. EFS was estimated using Kaplan-Meier method. IRC review was performed up clinical cutoff date of to 1 May 2015.
Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Percentage of Participants Who Died
Time frame: Baseline until death (up to 8.5 years overall)
Overall Survival (OS)
OS was defined as the time between the date of randomization and the date of death from any cause. OS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline until death (up to 8.5 years overall)
Change From Baseline (CFB) in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)-Physical Well Being Sub-scale Score
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Physical Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for physical well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better participant-reported outcome (PRO)/quality of life (QoL). In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
CFB in FACT-Lym-Social/Family Well-being Sub-scale Score
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Social/family Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for social/family well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
CFB in FACT-Lym-Emotional Well-Being Sub-scale Score
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Emotional Well-being sub-scale includes 6 items measured on 0-4 point scale. The total score for emotional well-being sub-scale is sum of each 6 items (range: 0-24). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
CFB in FACT-Lym-Functional Well-Being Sub-scale Score
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Functional Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for functional well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
CFB in FACT-Lym-Lymphoma Sub-scale Score
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Lymphoma scale includes 15 items measured on 0-4 point scale. The total score for lymphoma sub-scale is sum of each 15 items (range: 0-60). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
CFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories.
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4 and 14
CFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.
Time frame: Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final follow-up (up to 2 years after end of induction) (End of induction = up to Month 6)
CFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories.
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4 and 14
CFB in EQ-5D VAS Score During Maintenance Phase
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.
Time frame: Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction) (end of induction = up to Month 6)
CFB in Functional Assessment of Cancer Therapy - Generic (FACT-G) Score
The FACT-G is the sum of 4 sub-scales (physical, social, emotional and functional well-being) of FACT-Lym which includes total 27 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-108. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
CFB in FACT-Lym Trial Outcome Index (TOI)
TOI is the sum of 3 sub-scales (physical well-being, functional well-being, and Lymphoma sub-scale) of FACT-Lym which includes total 29 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
CFB in FACT-Lym Total Score
FACT-Lym total score is the sum of physical well-being score (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and Lymphoma sub-scale (15 items); responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Time to Deterioration of FACT-Lym TOI
The median time, in month, from date of randomization until a clinically meaningful decline from baseline in TOI or death, whichever occurred first. TOI: sum of physical well-being score,functional well-being score, and Lymphoma sub-scale of FACT-Lym; total 29 items, responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from baseline. Time to deterioration was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley. In timeframe, follow-up months represents months after end of induction (EOI) (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
Time frame: Baseline up to approximately 8.5 years
Percentage of Participants With Definitive Improvement (DI) From Baseline in FACT-Lym Instrument Scores
FACT-Lym: 42-items in 5 subscales. Responses to each item range from 0 (Not at all) to 4 (Very much). FACT-Lym Lymphoma subscale includes 15 items (total score range = 0-60). FACT-Lym TOI is sum of 3 subscales (physical well-being, functional well-being, lymphoma subscale) and includes 29 items (total score range = 0-116). FACT-Lym total score is sum of 42 items (total score ranges from 0-168). For all above, higher scores indicate a better PRO/QoL. DI from baseline: at least 3 point increase from baseline in FACT-Lym Lymphoma subscale; at least 6 point increase from baseline in FACT Lym TOI; at least 7 point increase from baseline in FACT Lym total scores. In timeframe, follow-up months represents months after EOI (e.g. Follow-up Month 2 is 2 months after EOI; EOI = up to Month 6).
Time frame: Baseline, Cycle 5 Day 1 (C5D1) (Cycle length = 28 days), Follow-up Months 6 (FUM6), 12 (FUM12), 18 (FUM18), 24 (FUM24), Extension Follow Up Month 6 (Extension FUM6)
| Milestone | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Started | 209 | 204 |
| Completed | 82 | 101 |
| Not completed | 127 | 103 |
| Withdrew: Death | 100 | 84 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Physician decision | 2 | 4 |
| Withdrew: Withdrawal by subject | 21 | 14 |
PD was assessed by an IRC according to the modified response criteria for indolent Non-Hodgkin's Lymphoma (iNHL) (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50 percent (%) increase from nadir in the sum of product diameter (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (example: splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of less than (\<) 1.0 cm must increase by greater than or equal to (≥) 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node greater than (\>) 1 cm in its short axis.
| participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death | 125 | 87 |
PFS was defined as the time from randomization to the first occurrence of PD or death as assessed by an IRC according to the modified response criteria for iNHL (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
| months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Progression-Free Survival (PFS) as Assessed by IRC | 14.1 (11.7 to 16.6) | 29.2 (20.5 to NA) |
PD was assessed by an investigator according to the modified response criteria for iNHL (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis.
| participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Number of Participants With PD or Death as Assessed by Investigator | 152 | 132 |
PFS was defined as the time from randomization to the first occurrence of PD as assessed by an investigator according to the modified response criteria for iNHL (Modified Cheson et al, 2007), or death from any cause on study. PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| PFS as Assessed by Investigator | 14.1 (12.6 to 16.2) | 25.8 (20.1 to 36.5) |
Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. IRC review was performed up clinical cutoff date of to 1 May 2015.
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Percentage of Participants With Objective Response as Assessed by IRC | 77.5 (71.24 to 82.98) | 75.5 (69.00 to 81.23) |
Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Percentage of Participants With Objective Response as Assessed by Investigator | 83.3 (77.49 to 88.05) | 82.4 (76.42 to 87.32) |
BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan \& no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic \& hepatic nodules, involvement of other organs is usually assessable \& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions (e.g., splenic or hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| CR | 17.2 (12.37 to 23.04) | 16.2 (11.40 to 21.96) |
| PR | 60.3 (53.31 to 66.97) | 59.3 (52.23 to 66.12) |
| SD | 12.0 (7.89 to 17.15) | 13.7 (9.32 to 19.22) |
| PD | 5.7 (3.00 to 9.81) | 4.9 (2.38 to 8.83) |
| Unable to evaluate | 1.0 (0.12 to 3.41) | 1.0 (0.12 to 3.50) |
| Missing | 3.8 (1.67 to 7.40) | 4.9 (2.38 to 8.83) |
BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain the criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| CR | 21.5 (16.16 to 27.73) | 23.5 (17.89 to 29.96) |
| PR | 61.7 (54.76 to 68.34) | 58.8 (51.74 to 65.65) |
| SD | 6.7 (3.71 to 10.98) | 6.4 (3.44 to 10.65) |
| PD | 4.8 (2.32 to 8.62) | 6.4 (3.44 to 10.65) |
| Unable to evaluate | 1.4 (0.30 to 4.14) | 0.5 (0.01 to 2.70) |
| Missing | 3.8 (1.67 to 7.40) | 4.4 (2.04 to 8.21) |
BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan \& no new sites; no increase in size of other nodes, liver or spleen; with exception of splenic \& hepatic nodules, involvement of other organs is usually assessable \& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or size of other lesions (e.g., splenic/hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| CR | 12.0 (7.93 to 17.23) | 11.8 (7.69 to 17.00) |
| PR | 52.4 (45.38 to 59.35) | 54.9 (47.80 to 61.86) |
| SD | 10.1 (6.36 to 15.02) | 11.8 (7.69 to 17.00) |
| PD | 10.6 (6.75 to 15.58) | 8.8 (5.31 to 13.59) |
| Unable to Evaluate | 2.9 (1.07 to 6.17) | 2.0 (0.54 to 4.94) |
| Missing | 12.0 (7.93 to 17.23) | 10.8 (6.88 to 15.87) |
BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| CR | 15.8 (11.12 to 21.45) | 17.2 (12.25 to 23.04) |
| PR | 53.1 (46.10 to 60.03) | 60.3 (53.23 to 67.06) |
| SD | 4.3 (1.99 to 8.02) | 3.9 (1.71 to 7.58) |
| PD | 12.0 (7.89 to 17.15) | 9.3 (5.70 to 14.16) |
| Unable to Evaluate | 2.9 (1.06 to 6.14) | 0.5 (0.01 to 2.70) |
| Missing | 12.0 (7.89 to 17.15) | 8.8 (5.31 to 13.59) |
Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. IRC review was performed up clinical cutoff date of to 1 May 2015.
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC | 64.4 (57.51 to 70.92) | 66.7 (59.75 to 73.10) |
Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by Investigator | 68.9 (62.15 to 75.11) | 77.5 (71.09 to 82.99) |
DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable evidence of disease \& disease-related symptoms if present before therapy; liver, spleen returned to normal size; if bone marrow involved by lymphoma before treatment, infiltrate must be cleared on repeat bone marrow biopsy. PR: at least 50% measurable disease regressed vs. to baseline scan and no new sites; no increase in size of other nodes/liver/spleen, exception: splenic, hepatic nodules; other organs involved is usually assessable; no measurable disease present. PD: any new lesion \>1.5 cm in any axis appear during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR estimated using Kaplan-Meier method. IRC review performed up to clinical cutoff date 1 May 2015.
| months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Duration of Response (DoR) as Assessed by IRC | 12.7 (10.4 to 14.1) | 38.5 (25.4 to NA) |
DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy; liver, spleen returned to normal size (if enlarged at baseline); if bone marrow was involved by lymphoma prior to treatment, infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic, hepatic nodules; involvement of other organs is usually assessable; no presence of measurable disease. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR was estimated using Kaplan-Meier method.
| months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Duration of Response (DoR) as Assessed by Investigator | 12.7 (11.1 to 15.5) | 32.3 (20.8 to 39.0) |
DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method. IRC review was performed up clinical cutoff date of to 1 May 2015.
| months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Disease-Free Survival (DFS) in Participants With CR as Assessed by IRC | 13.2 (8.5 to NA) | NA (NA to NA) |
DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method.
| months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Disease-Free Survival (DFS) in Participants With CR as Assessed by Investigator | 20.0 (8.6 to 31.0) | 36.0 (26.6 to 68.2) |
EFS was defined as the time between the date of randomization and the date of PD/relapse based on IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]), death from any cause on study, or start of a new anti-lymphoma therapy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. EFS was estimated using Kaplan-Meier method. IRC review was performed up clinical cutoff date of to 1 May 2015.
| months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Event-free Survival (EFS) as Assessed by IRC | 13.7 (11.4 to 15.5) | 25.3 (13.9 to 35.0) |
| percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Percentage of Participants Who Died | 49.3 | 41.2 |
OS was defined as the time between the date of randomization and the date of death from any cause. OS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Overall Survival (OS) | 65.6 (48.5 to 87.8) | 88.3 (71.1 to NA) |
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Physical Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for physical well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better participant-reported outcome (PRO)/quality of life (QoL). In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 22.58 ± 5.23 | 22.76 ± 4.61 |
| CFB at Cycle 3 Day 1 | -1.56 ± 5.49 | -0.69 ± 4.06 |
| CFB at Cycle 4 Day 1 | -6.80 ± 4.21 | -3.00 ± 2.83 |
| CFB at Cycle 5 Day 1 | -1.82 ± 5.06 | -0.72 ± 4.16 |
| CFB at End of Induction Treatment | -1.00 ± 5.14 | -0.61 ± 4.62 |
| CFB at Follow-up Month 2 | 0.62 ± 5.14 | 0.58 ± 4.45 |
| CFB at Follow-up Month 4 | 0.53 ± 4.58 | 0.88 ± 4.47 |
| CFB at Follow-up Month 6 | 0.29 ± 3.74 | 0.91 ± 3.82 |
| CFB at Follow-up Month 8 | -0.01 ± 3.53 | 0.87 ± 3.96 |
| CFB at Follow-up Month 10 | 0.06 ± 4.16 | 0.56 ± 3.81 |
| CFB at Follow-up Month 12 | 0.26 ± 4.02 | 0.74 ± 4.24 |
| CFB at Follow-up Month 14 | 0.03 ± 4.14 | 0.71 ± 3.94 |
| CFB at Follow-up Month 16 | -0.10 ± 3.49 | 1.31 ± 3.68 |
| CFB at Follow-up Month 18 | -0.22 ± 3.64 | 0.92 ± 3.99 |
| CFB at Follow-up Month 20 | -0.36 ± 3.70 | 0.74 ± 3.69 |
| CFB at Follow-up Month 22 | -0.25 ± 3.93 | 0.40 ± 4.47 |
| CFB at Follow-up Month 24 | -0.77 ± 4.16 | 0.52 ± 4.42 |
| CFB at Final Follow-up | 0.16 ± 4.17 | 0.22 ± 4.47 |
| CFB at Extension Follow-up Month 6 | 0.36 ± 3.48 | 0.57 ± 4.71 |
| CFB at Extension Follow-up Month 18 | 0.80 ± 2.54 | 1.19 ± 4.98 |
| CFB at Extension Follow-up Month 24 | 1.53 ± 5.96 | 0.56 ± 5.26 |
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Social/family Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for social/family well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 22.04 ± 5.65 | 22.14 ± 5.51 |
| CFB at Cycle 3 Day 1 | -0.21 ± 3.59 | -0.10 ± 3.87 |
| CFB at Cycle 4 Day 1 | -1.00 ± 3.67 | 3.11 ± 2.83 |
| CFB at Cycle 5 Day 1 | -0.34 ± 4.32 | -0.34 ± 4.33 |
| CFB at End of Induction Treatment | -0.65 ± 5.21 | -0.88 ± 3.60 |
| CFB at Follow-up Month 2 | -0.02 ± 4.83 | -0.57 ± 5.37 |
| CFB at Follow-up Month 4 | 0.27 ± 4.65 | -0.26 ± 5.02 |
| CFB at Follow-up Month 6 | 0.05 ± 4.46 | -0.08 ± 4.64 |
| CFB at Follow-up Month 8 | -0.68 ± 3.67 | -0.37 ± 4.99 |
| CFB at Follow-up Month 10 | 0.56 ± 5.00 | 0.13 ± 5.14 |
| CFB at Follow-up Month 12 | 0.06 ± 5.89 | -0.47 ± 5.64 |
| CFB at Follow-up Month 14 | 0.56 ± 3.28 | -0.03 ± 4.16 |
| CFB at Follow-up Month 16 | 0.36 ± 6.79 | -0.15 ± 5.28 |
| CFB at Follow-up Month 18 | 0.44 ± 6.23 | 0.04 ± 5.35 |
| CFB at Follow-up Month 20 | -0.66 ± 4.28 | 0.00 ± 5.75 |
| CFB at Follow-up Month 22 | 0.29 ± 7.12 | -0.50 ± 5.02 |
| CFB at Follow-up Month 24 | -1.29 ± 3.91 | -0.41 ± 5.24 |
| CFB at Final Follow-up | -0.19 ± 4.91 | -0.52 ± 5.56 |
| CFB at Extension Follow-up Month 6 | -0.35 ± 2.49 | -0.16 ± 4.92 |
| CFB at Extension Follow-up Month 18 | -0.15 ± 2.92 | 0.71 ± 5.26 |
| CFB at Extension Follow-up Month 24 | -0.41 ± 3.18 | 0.44 ± 5.02 |
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Emotional Well-being sub-scale includes 6 items measured on 0-4 point scale. The total score for emotional well-being sub-scale is sum of each 6 items (range: 0-24). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 17.38 ± 4.45 | 17.81 ± 4.33 |
| CFB at Cycle 3 Day 1 | 0.61 ± 3.04 | 0.78 ± 3.14 |
| CFB at Cycle 4 Day 1 | -0.60 ± 3.85 | 3.40 ± 4.42 |
| CFB at Cycle 5 Day 1 | 0.37 ± 3.08 | 0.50 ± 3.52 |
| CFB at End of Induction Treatment | 0.53 ± 3.57 | 0.59 ± 4.03 |
| CFB at Follow-up Month 2 | 0.66 ± 3.89 | 0.67 ± 3.83 |
| CFB at Follow-up Month 4 | 1.34 ± 3.54 | 0.95 ± 3.51 |
| CFB at Follow-up Month 6 | 0.89 ± 3.57 | 0.96 ± 3.44 |
| CFB at Follow-up Month 8 | 0.26 ± 3.35 | 0.97 ± 3.34 |
| CFB at Follow-up Month 10 | 0.69 ± 3.31 | 1.32 ± 3.23 |
| CFB at Follow-up Month 12 | -0.07 ± 3.88 | 0.95 ± 3.29 |
| CFB at Follow-up Month 14 | 0.46 ± 3.22 | 1.07 ± 3.82 |
| CFB at Follow-up Month 16 | 0.13 ± 3.87 | 1.04 ± 3.69 |
| CFB at Follow-up Month 18 | 0.42 ± 3.36 | 1.00 ± 3.38 |
| CFB at Follow-up Month 20 | -0.43 ± 2.90 | 0.94 ± 4.28 |
| CFB at Follow-up Month 22 | 0.18 ± 2.81 | 0.97 ± 3.79 |
| CFB at Follow-up Month 24 | 0.06 ± 3.20 | 1.12 ± 3.78 |
| CFB at Final Follow-up | 0.38 ± 3.77 | 0.34 ± 4.37 |
| CFB at Extension Follow-up Month 6 | -0.44 ± 3.26 | 0.39 ± 3.99 |
| CFB at Extension Follow-up Month 18 | -0.08 ± 3.80 | 0.75 ± 3.85 |
| CFB at Extension Follow-up Month 24 | 1.04 ± 4.16 | 0.97 ± 4.36 |
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Functional Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for functional well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 17.98 ± 6.31 | 17.90 ± 6.08 |
| CFB at Cycle 3 Day 1 | -0.54 ± 4.65 | 0.38 ± 4.66 |
| CFB at Cycle 4 Day 1 | -0.80 ± 2.28 | 1.78 ± 4.91 |
| CFB at Cycle 5 Day 1 | -0.71 ± 5.04 | 0.67 ± 5.35 |
| CFB at End of Induction Treatment | -0.50 ± 5.50 | 0.00 ± 5.25 |
| CFB at Follow-up Month 2 | 0.31 ± 5.27 | 0.65 ± 5.38 |
| CFB at Follow-up Month 4 | 0.24 ± 5.11 | 1.31 ± 5.86 |
| CFB at Follow-up Month 6 | 0.95 ± 4.58 | 1.26 ± 5.08 |
| CFB at Follow-up Month 8 | -0.27 ± 4.38 | 0.92 ± 5.45 |
| CFB at Follow-up Month 10 | 1.09 ± 4.25 | 1.00 ± 5.52 |
| CFB at Follow-up Month 12 | 0.18 ± 5.59 | 1.78 ± 6.04 |
| CFB at Follow-up Month 14 | 1.16 ± 4.27 | 1.22 ± 4.84 |
| CFB at Follow-up Month 16 | 0.91 ± 3.97 | 1.69 ± 5.95 |
| CFB at Follow-up Month 18 | 0.21 ± 4.12 | 1.84 ± 5.77 |
| CFB at Follow-up Month 20 | -0.27 ± 4.90 | 1.43 ± 6.14 |
| CFB at Follow-up Month 22 | -0.32 ± 5.70 | 0.82 ± 5.00 |
| CFB at Follow-up Month 24 | -0.96 ± 4.36 | 0.98 ± 5.87 |
| CFB at Final Follow-up | -0.08 ± 4.94 | 0.50 ± 6.19 |
| CFB at Extension Follow-up Month 6 | 1.01 ± 3.51 | 0.85 ± 6.65 |
| CFB at Extension Follow-up Month 18 | 0.96 ± 4.51 | 1.90 ± 6.50 |
| CFB at Extension Follow-up Month 24 | 2.22 ± 3.34 | 2.62 ± 6.95 |
The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Lymphoma scale includes 15 items measured on 0-4 point scale. The total score for lymphoma sub-scale is sum of each 15 items (range: 0-60). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 44.79 ± 9.66 | 45.61 ± 9.17 |
| CFB at Cycle 3 Day 1 | 0.98 ± 6.97 | 1.24 ± 5.71 |
| CFB at Cycle 4 Day 1 | -2.80 ± 5.76 | 9.50 ± 3.54 |
| CFB at Cycle 5 Day 1 | 0.75 ± 6.79 | 1.41 ± 6.21 |
| CFB at End of Induction Treatment | 1.64 ± 7.10 | 0.74 ± 7.89 |
| CFB at Follow-up Month 2 | 3.44 ± 6.78 | 2.45 ± 6.22 |
| CFB at Follow-up Month 4 | 2.77 ± 6.71 | 2.39 ± 6.54 |
| CFB at Follow-up Month 6 | 2.33 ± 6.44 | 3.00 ± 7.05 |
| CFB at Follow-up Month 8 | 1.79 ± 6.01 | 2.52 ± 6.69 |
| CFB at Follow-up Month 10 | 1.90 ± 6.78 | 2.28 ± 6.82 |
| CFB at Follow-up Month 12 | 2.12 ± 6.47 | 2.89 ± 6.42 |
| CFB at Follow-up Month 14 | 0.48 ± 6.64 | 2.58 ± 6.37 |
| CFB at Follow-up Month 16 | 0.44 ± 7.79 | 3.27 ± 6.14 |
| CFB at Follow-up Month 18 | 1.18 ± 6.09 | 2.91 ± 6.79 |
| CFB at Follow-up Month 20 | 0.57 ± 7.43 | 2.83 ± 6.41 |
| CFB at Follow-up Month 22 | 1.89 ± 8.62 | 2.55 ± 6.58 |
| CFB at Follow-up Month 24 | 0.66 ± 7.59 | 2.73 ± 6.48 |
| CFB at Final Follow-up | 1.62 ± 7.17 | 1.33 ± 7.38 |
| CFB at Extension Follow-up Month 6 | 0.92 ± 5.06 | 2.98 ± 7.22 |
| CFB at Extension Follow-up Month 18 | 1.80 ± 8.30 | 2.35 ± 5.72 |
| CFB at Extension Follow-up Month 24 | 4.89 ± 6.67 | 2.23 ± 6.85 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories.
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 0.77 ± 0.22 | 0.79 ± 0.20 |
| CFB at Cycle 3 Day 1 | 0.03 ± 0.21 | 0.00 ± 0.19 |
| CFB at Cycle 4 Day 1 | -0.10 ± 0.23 | -0.07 ± 0.41 |
| CFB at Cycle 5 Day 1 | 0.01 ± 0.21 | 0.02 ± 0.20 |
| CFB at End of Induction Treatment | 0.01 ± 0.22 | 0.01 ± 0.20 |
| CFB at Follow-up Month 2 | 0.06 ± 0.24 | 0.04 ± 0.18 |
| CFB at Follow-up Month 4 | — | -0.12 ± 0.00 |
| CFB at Follow-up Month 14 | 0.12 ± NA | — |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| CFB at Follow-up Month 2 | — | -0.15 ± 0.22 |
| CFB at Follow-up Month 4 | 0.15 ± NA | 0.03 ± 0.22 |
| CFB at Follow-up Month 6 | 0.15 ± NA | 0.04 ± 0.19 |
| CFB at Follow-up Month 8 | 0.15 ± NA | 0.04 ± 0.21 |
| CFB at Follow-up Month 10 | 0.15 ± NA | 0.03 ± 0.20 |
| CFB at Follow-up Month 12 | — | 0.06 ± 0.18 |
| CFB at Follow-up Month 14 | — | 0.06 ± 0.19 |
| CFB at Follow-up Month 16 | — | 0.05 ± 0.19 |
| CFB at Follow-up Month 18 | — | 0.05 ± 0.18 |
| CFB at Follow-up Month 20 | — | 0.05 ± 0.20 |
| CFB at Follow-up Month 22 | — | 0.05 ± 0.24 |
| CFB at Follow-up Month 24 | — | 0.03 ± 0.22 |
| CFB at Final Follow-up | — | 0.03 ± 0.25 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories.
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 69.48 ± 20.71 | 68.03 ± 21.69 |
| CFB at Cycle 3 Day 1 | 0.91 ± 19.38 | 3.32 ± 15.99 |
| CFB at Cycle 4 Day 1 | -14.00 ± 33.29 | -4.33 ± 42.15 |
| CFB at Cycle 5 Day 1 | 0.35 ± 20.79 | 5.17 ± 17.35 |
| CFB at End of Induction Treatment | 5.71 ± 61.88 | 5.82 ± 22.20 |
| CFB at Follow-up Month 2 | 5.19 ± 19.12 | 6.85 ± 18.95 |
| CFB at Follow-up Month 4 | — | 0.00 ± 14.14 |
| CFB at Follow-up Month 14 | 10.00 ± NA | — |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.
| units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| CFB at Follow-up Month 2 | — | -40.00 ± NA |
| CFB at Follow-up Month 4 | 5.00 ± NA | 5.59 ± 19.61 |
| CFB at Follow-up Month 6 | 5.00 ± NA | 6.04 ± 19.00 |
| CFB at Follow-up Month 8 | 5.00 ± NA | 4.79 ± 17.18 |
| CFB at Follow-up Month 10 | -15.00 ± NA | 4.62 ± 16.28 |
| CFB at Follow-up Month 12 | — | 5.73 ± 16.04 |
| CFB at Follow-up Month 14 | — | 5.45 ± 17.36 |
| CFB at Follow-up Month 16 | — | 6.66 ± 17.44 |
| CFB at Follow-up Month 18 | — | 6.13 ± 19.44 |
| CFB at Follow-up Month 20 | — | 7.56 ± 15.43 |
| CFB at Follow-up Month 22 | — | 6.97 ± 15.55 |
| CFB at Follow-up Month 24 | — | 8.28 ± 16.23 |
| CFB at Final Follow-up | — | 4.47 ± 14.91 |
The FACT-G is the sum of 4 sub-scales (physical, social, emotional and functional well-being) of FACT-Lym which includes total 27 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-108. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| Units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 79.86 ± 16.25 | 80.78 ± 16.27 |
| CFB at Cycle 3 Day 1 | -1.87 ± 12.28 | 0.11 ± 10.30 |
| CFB at Cycle 4 Day 1 | -9.37 ± 9.89 | 0.52 ± 4.98 |
| CFB at Cycle 5 Day 1 | -2.44 ± 12.01 | 0.06 ± 11.13 |
| CFB at End of Induction Treatment | -1.84 ± 13.83 | -0.92 ± 11.77 |
| CFB at Follow-up Month 2 | 1.53 ± 13.42 | 1.22 ± 12.01 |
| CFB at Follow-up Month 4 | 2.55 ± 11.47 | 3.06 ± 13.00 |
| CFB at Follow-up Month 6 | 2.54 ± 10.68 | 3.24 ± 11.40 |
| CFB at Follow-up Month 8 | -0.53 ± 10.15 | 2.49 ± 11.45 |
| CFB at Follow-up Month 10 | 2.29 ± 11.39 | 3.46 ± 11.83 |
| CFB at Follow-up Month 12 | 0.68 ± 13.16 | 2.82 ± 14.29 |
| CFB at Follow-up Month 14 | 2.48 ± 9.42 | 2.94 ± 11.97 |
| CFB at Follow-up Month 16 | 1.54 ± 10.61 | 4.09 ± 12.87 |
| CFB at Follow-up Month 18 | 1.16 ± 11.57 | 4.06 ± 13.36 |
| CFB at Follow-up Month 20 | -1.21 ± 12.25 | 3.05 ± 14.29 |
| CFB at Follow-up Month 22 | 0.64 ± 14.27 | 1.80 ± 12.43 |
| CFB at Follow-up Month 24 | -2.39 ± 9.32 | 2.28 ± 13.83 |
| CFB at Final Follow-up | 0.50 ± 11.25 | 0.78 ± 14.94 |
| CFB at Extension Follow Up Month 6 | 0.48 ± 8.71 | 1.74 ± 14.23 |
| CFB at Extension Follow Up Month 18 | 2.29 ± 8.40 | 4.56 ± 15.02 |
| CFB at Extension Follow Up Month 24 | 4.48 ± 11.10 | 4.47 ± 15.22 |
TOI is the sum of 3 sub-scales (physical well-being, functional well-being, and Lymphoma sub-scale) of FACT-Lym which includes total 29 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| Units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 84.66 ± 19.36 | 84.76 ± 18.97 |
| CFB at Cycle 3 Day 1 | -1.94 ± 17.96 | 1.81 ± 13.88 |
| CFB at Cycle 4 Day 1 | -10.40 ± 10.38 | 26.44 ± 19.51 |
| CFB at Cycle 5 Day 1 | -1.38 ± 15.38 | 2.37 ± 14.15 |
| CFB at End of Induction Treatment | -0.52 ± 17.23 | 0.40 ± 16.45 |
| CFB at Follow-up Month 2 | 3.75 ± 15.36 | 4.60 ± 14.85 |
| CFB at Follow-up Month 4 | 3.81 ± 13.39 | 5.18 ± 17.06 |
| CFB at Follow-up Month 6 | 3.26 ± 12.19 | 6.07 ± 13.72 |
| CFB at Follow-up Month 8 | 1.36 ± 12.39 | 5.36 ± 14.21 |
| CFB at Follow-up Month 10 | 3.52 ± 13.16 | 4.94 ± 15.96 |
| CFB at Follow-up Month 12 | 2.05 ± 15.14 | 6.13 ± 15.72 |
| CFB at Follow-up Month 14 | 2.25 ± 11.92 | 5.13 ± 14.30 |
| CFB at Follow-up Month 16 | 0.75 ± 14.15 | 6.78 ± 15.11 |
| CFB at Follow-up Month 18 | 1.36 ± 11.30 | 7.26 ± 14.62 |
| CFB at Follow-up Month 20 | -0.64 ± 15.21 | 6.36 ± 14.99 |
| CFB at Follow-up Month 22 | 2.26 ± 14.54 | 5.30 ± 17.88 |
| CFB at Follow-up Month 24 | -0.14 ± 13.44 | 5.30 ± 17.88 |
| CFB at Final Follow-up | 0.84 ± 14.80 | 3.84 ± 16.22 |
| CFB at Extension Follow Up Month 6 | 2.30 ± 10.77 | 5.53 ± 18.44 |
| CFB at Extension Follow Up Month 18 | 4.02 ± 14.01 | 7.31 ± 15.69 |
| CFB at Extension Follow Up Month 24 | 10.04 ± 13.35 | 7.07 ± 17.59 |
FACT-Lym total score is the sum of physical well-being score (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and Lymphoma sub-scale (15 items); responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| Units on a scale | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Baseline | 124.56 ± 24.17 | 126.22 ± 23.98 |
| CFB at Cycle 3 Day 1 | -0.74 ± 17.91 | 1.33 ± 13.89 |
| CFB at Cycle 4 Day 1 | -12.16 ± 14.80 | 22.53 ± 16.23 |
| CFB at Cycle 5 Day 1 | -1.68 ± 16.61 | 1.71 ± 15.23 |
| CFB at End of Induction Treatment | 0.02 ± 18.55 | 0.35 ± 18.29 |
| CFB at Follow-up Month 2 | 5.10 ± 17.73 | 3.54 ± 15.45 |
| CFB at Follow-up Month 4 | 5.40 ± 16.29 | 5.50 ± 17.76 |
| CFB at Follow-up Month 6 | 5.03 ± 15.01 | 6.57 ± 15.96 |
| CFB at Follow-up Month 8 | 1.48 ± 14.27 | 5.18 ± 15.61 |
| CFB at Follow-up Month 10 | 4.58 ± 16.39 | 5.70 ± 16.89 |
| CFB at Follow-up Month 12 | 2.97 ± 17.84 | 5.88 ± 18.93 |
| CFB at Follow-up Month 14 | 3.18 ± 13.85 | 5.92 ± 17.06 |
| CFB at Follow-up Month 16 | 2.25 ± 14.98 | 7.59 ± 16.97 |
| CFB at Follow-up Month 18 | 2.16 ± 15.38 | 6.99 ± 18.27 |
| CFB at Follow-up Month 20 | -0.89 ± 16.34 | 5.66 ± 18.90 |
| CFB at Follow-up Month 22 | 2.15 ± 19.03 | 4.59 ± 17.98 |
| CFB at Follow-up Month 24 | -2.13 ± 15.74 | 5.28 ± 18.75 |
| CFB at Final follow-up | 2.15 ± 16.60 | 2.55 ± 20.11 |
| CFB at Extension Follow Up Month 6 | 1.22 ± 11.67 | 5.14 ± 20.30 |
| CFB at Extension Follow Up Month 18 | 4.92 ± 14.73 | 6.88 ± 19.24 |
| CFB at Extension Follow Up Month 24 | 9.69 ± 15.88 | 6.13 ± 20.32 |
The median time, in month, from date of randomization until a clinically meaningful decline from baseline in TOI or death, whichever occurred first. TOI: sum of physical well-being score,functional well-being score, and Lymphoma sub-scale of FACT-Lym; total 29 items, responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from baseline. Time to deterioration was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley. In timeframe, follow-up months represents months after end of induction (EOI) (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).
| Months | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| Time to Deterioration of FACT-Lym TOI | 5.6 (3.9 to 7.0) | 8.0 (5.9 to 14.7) |
FACT-Lym: 42-items in 5 subscales. Responses to each item range from 0 (Not at all) to 4 (Very much). FACT-Lym Lymphoma subscale includes 15 items (total score range = 0-60). FACT-Lym TOI is sum of 3 subscales (physical well-being, functional well-being, lymphoma subscale) and includes 29 items (total score range = 0-116). FACT-Lym total score is sum of 42 items (total score ranges from 0-168). For all above, higher scores indicate a better PRO/QoL. DI from baseline: at least 3 point increase from baseline in FACT-Lym Lymphoma subscale; at least 6 point increase from baseline in FACT Lym TOI; at least 7 point increase from baseline in FACT Lym total scores. In timeframe, follow-up months represents months after EOI (e.g. Follow-up Month 2 is 2 months after EOI; EOI = up to Month 6).
| Percentage of participants | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| C5D1 (>=3 pt increase) | 30.3 | 41.7 |
| FUM6 (>=3 pt increase) | 37.9 | 47.1 |
| FUM12 (>=3 pt increase) | 36.7 | 46.5 |
| FUM18 (>=3 pt increase) | 35.6 | 53.0 |
| FUM24 (>=3 pt increase) | 35.3 | 50 |
| Ext FUM6 (>=3 pt increase) | 36.0 | 57.8 |
| C5D1 (>=6 pt increase) | 23.1 | 34.4 |
| FUM6 (>=6 pt increase) | 29.5 | 43.7 |
| FUM12 (>=6 pt increase) | 26.2 | 47.0 |
| FUM18 (>=6 pt increase) | 28.9 | 51.8 |
| FUM24 (>=6 pt increase) | 26.5 | 48.0 |
| Ext FUM6 (>=6 pt increase) | 44 | 56.9 |
| C5D1 (>=7 pt increase) | 24.4 | 28.0 |
| FUM6 (>=7 pt increase) | 34.1 | 40.3 |
| FUM12 (>=7 pt increase) | 31.1 | 45.0 |
| FUM18 (>=7 pt increase) | 31.1 | 43.4 |
| FUM24 (>=7 pt increase) | 20.6 | 42.7 |
| Ext FUM6 (>=7 pt increase) | 32 | 47.7 |
Collected over Baseline up to 8.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bendamustine Alone | — | 76/203 (37.4%) | 194/203 (95.6%) |
| Obinutuzumab + Bendamustine | — | 91/204 (44.6%) | 200/204 (98%) |
| Event | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| PNEUMONIAInfections and infestations | 12/203 | 7/204 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 6/203 | 11/204 |
| SEPSISInfections and infestations | 7/203 | 6/204 |
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 3/203 | 7/204 |
| NEUTROPENIABlood and lymphatic system disorders | 1/203 | 6/204 |
| PYREXIAGeneral disorders | 3/203 | 6/204 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/203 | 5/204 |
| ANAEMIABlood and lymphatic system disorders | 3/203 | 3/204 |
| DIARRHOEAGastrointestinal disorders | 3/203 | 0/204 |
| BRONCHITISInfections and infestations | 3/203 | 1/204 |
| Event | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---|---|---|
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 115/203 | 125/204 |
| NAUSEAGastrointestinal disorders | 123/203 | 107/204 |
| FATIGUEGeneral disorders | 67/203 | 81/204 |
| NEUTROPENIABlood and lymphatic system disorders | 59/203 | 74/204 |
| COUGHRespiratory, thoracic and mediastinal disorders | 40/203 | 64/204 |
| DIARRHOEAGastrointestinal disorders | 61/203 | 57/204 |
| VOMITINGGastrointestinal disorders | 54/203 | 44/204 |
| PYREXIAGeneral disorders | 36/203 | 54/204 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 50/203 | 26/204 |
| CONSTIPATIONGastrointestinal disorders | 40/203 | 42/204 |
| Age, Continuous(Years) | Bendamustine Alone | Obinutuzumab + Bendamustine | Total |
|---|---|---|---|
| Mean | 61.9 ± 11.5 | 62.0 ± 11.3 | 61.9 ± 11.4 |
| Sex: Female, Male(Participants) | Bendamustine Alone | Obinutuzumab + Bendamustine | Total |
|---|---|---|---|
| Female | 87 | 88 | 175 |
| Male | 122 | 116 | 238 |
| Race/Ethnicity, Customized(Participants) | Bendamustine Alone | Obinutuzumab + Bendamustine | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 11 |
| Not Hispanic or Latino | 174 | 183 | 357 |
| Not Stated | 30 | 15 | 45 |
| Race/Ethnicity, Customized(Participants) | Bendamustine Alone | Obinutuzumab + Bendamustine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 3 | 6 | 9 |
| Black or African American | 3 | 5 | 8 |
| Multiple | 1 | 0 | 1 |
| Unknown | 19 | 12 | 31 |
| White | 181 | 180 | 361 |
Showing the first 100 of 121 sites across 14 countries. Choose a country and city above to see the rest.
Ran from Apr 2010 to primary completion in Sep 2014, 53 months.
Results were first posted in Nov 2016, 2 years 1 month after primary completion. A results delay was requested in Sep 2015.
Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 53 months is below that.
Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab